<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               1 INDICATIONS AND USAGE<BR>               <BR>                  Enter section text here<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        Letrozole is an aromatase inhibitor indicated for: <BR>                        <BR>                           Adjuvant treatment of postmenopausal women with hormone receptor positive <BR>early breast cancer. (1.1) <BR>                           Extended adjuvant treatment of postmenopausal women with early breast cancer <BR>who have received prior standard adjuvant tamoxifen therapy. (1.2) <BR>                           First and second-line treatment of postmenopausal women with hormone <BR>receptor positive or unknown advanced breast cancer. (1.3) <BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.1 Adjuvant Treatment of Early Breast Cancer<BR>                     <BR>                        <BR>                           Letrozole <BR>tablets are indicated for the adjuvant treatment of postmenopausal women with <BR>hormone receptor positive early breast cancer.<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.2 Extended Adjuvant Treatment of Early Breast Cancer<BR>                     <BR>                        Letrozole tablets are indicated for the extended adjuvant <BR>treatment of early breast cancer in postmenopausal women, who have received 5 <BR>years of adjuvant tamoxifen therapy. The effectiveness of letrozole in extended <BR>adjuvant treatment of early breast cancer is based on an analysis of <BR>disease-free survival in patients treated with letrozole tablets for a median of <BR>60 months [see Clinical Studies <BR>(14.2, 14.3)]. <BR><BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.3 First and Second-Line Treatment of Advanced Breast Cancer<BR>                     <BR>                        Letrozole tablets are indicated for first-line treatment of <BR>postmenopausal women with hormone receptor positive or unknown, locally advanced <BR>or metastatic breast cancer. Letrozole tablets are also indicated for the <BR>treatment of advanced breast cancer in postmenopausal women with disease <BR>progression following antiestrogen therapy [see Clinical Studies <BR>(14.4, 14.5)]. <BR><BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>